KRAS and non-small cell lung carcinoma: Remarkedly, based on a study of 124 advanced NSCLC patients harboring KRASG12C mutation, Lumakras (sotorasib, AMG510) were approved for KRASG12C NSCLC patients by the U.S. Food and Drug Administration (FDA) recently, which is the first approved targeted therapy for tumors with KRAS mutation [18, 19].